Your Search Returned 413 tagged news reports
The online video asset manager revealed that it's in talks with several potential buyers of the company. Then again, it remains to be seen how many are still interested in KIT now that news of a potential acquisition has moved the stock 50% higher.
Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....You know a company isn't in a good place when investors enthusiastically greet an event that could cause its demise...JNJ ) filed with the FDA to
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...So what: With Dendreon closing at just $6.25 on Tuesday,
Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....Nobody likes to pay taxes, but sooner or later, the IRS will collect what's coming to it. If you can pay less now in order to save more later -- a lot
Since we looked at Regeneron Pharmaceuticals last year , the company has lost a point. A big jump in debt is responsible for the drop, although shareholders certainly can't complain about the stock's having more than doubled in the past year. Nothing'
Since we looked at Kodiak Oil & Gas last year , the company has dropped two points. Despite even faster growth and becoming profitable, the company's balance sheet has been ravaged with an increase in debt, although the shares are still up about 25%
Let's take a look at how the company got there to find out whether cloudy skies remain on the horizon. How it got here Fossil's year had been going rather well ... and then its first quarter numbers came out . Now it's one of the few upscale retail
According to clinical trial data reported Saturday, men who took Johnson & Johnson's pill Zytiga lived twice as long before their cancer worsened compared with patients who took a dummy pill. The men also appeared to live longer in general, although
Two months ago, a late-stage trial found that Zytiga, a Johnson & Johnson treatment for prostate cancer, improved survival in patients who had not received chemo the pill delayed cancer growth and helped patients live longer versus a placebo. And so,
In a large study, intermittent hormonal therapy proved to be less effective than continuous therapy for certain men with metastatic prostate cancer. The finding is striking and surprising because it goes against the conventional belief, said Dr. Maha